Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]

Abstract Background The treatment of Herpes-simplex-virus-encephalitis (HSVE) remains a major unsolved problem in Neurology. Current gold standard for therapy is acyclovir, a drug that inhibits viral replication. Despite antiviral treatment, mortality remains up to 15%, less than 20% of patients are able to go back to work, and the majority of patients suffer from severe disability. This is a discouraging, unsatisfactory situation for treating physicians, the disabled patients and their families, and constitutes an enormous burden to the public health services. The information obtained from ex... Mehr ...

Verfasser: Martinez-Torres, Francisco
Menon, Sanjay
Pritsch, Maria
Victor, Norbert
Jenetzky, Ekkehart
Jensen, Katrin
Schielke, Eva
Schmutzhard, Erich
de Gans, Jan
Chung, Chin-Hee
Luntz, Steffen
Hacke, Werner
Meyding-Lamadé, Uta
Dokumenttyp: Artikel
Erscheinungsdatum: 2008
Reihe/Periodikum: BMC Neurology ; volume 8, issue 1 ; ISSN 1471-2377
Verlag/Hrsg.: Springer Science and Business Media LLC
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29046458
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://dx.doi.org/10.1186/1471-2377-8-40